Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Pulmonology > ATS 2024 > Obstructive Sleep Apnea > Does PAP therapy truly reduce mortality in OSA?

Does PAP therapy truly reduce mortality in OSA?

Presented by
Dr Atul Malhotr, University of California San Diego, CA, USA
Conference
ATS 2024
Doi
https://doi.org/10.55788/3f24057f
    A systematic review and meta-analysis supports the use of positive airway pressure (PAP) therapy to reduce all-cause mortality in patients with obstructive sleep apnoea (OSA). According to the authors, future research should explore causal pathways and effect modifiers for the observed benefit of PAP therapy.

    “PAP therapy is the treatment of choice in patients with OSA, delivering marked improvements in patient-reported quality-of-life outcomes,” said Dr Atul Malhotr (University of California San Diego, CA, USA). “However, the impact of PAP therapy on all-cause mortality in this population is not clear.” The current systematic literature review and meta-analysis evaluated the association between all-cause mortality and PAP therapy in patients with OSA [1]. The authors included 10 randomised trials and 17 non-randomised studies with all-cause mortality as outcome measure, resulting in a total sample size of 1,164,880 patients. In addition, they included 6 randomised controlled trials and 5 non-randomised-controlled studies with cardiovascular mortality as an outcome measure.

    Overall, PAP therapy had a significant impact on all-cause mortality in patients with OSA (HR 0.63; 95% CI 0.56–0.72; P<0.001). Dr Malhotra mentioned that there was a trend towards a better treatment effect if the treatment adherence was higher: the treatment effect was 16% greater in patients using PAP therapy for at least 4 hours per night compared with patients who used PAP therapy for fewer than 4 hours per night. Next, PAP therapy reduced cardiovascular mortality in patients with OSA (HR 0.46; 95% CI 0.29–0.73; P=0.001).

    The current study thus indicates that PAP therapy is an effective treatment to reduce all-cause mortality in patients with OSA across diverse populations.

    1. Malhotra A, et al. All-cause mortality in OSA: systematic literature review including randomized trials and confounding adjusted non-randomized controlled studies and meta-analysis of PAP treatment. Sleep apnea unplugged: navigating a myriad of health outcomes. ATS 2024, 17–22 May, San Diego, USA.




    Posted on